Pontine Glioma - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Pontine Glioma - Pipeline Review, H1 2016', provides an overview of the Pontine Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pontine Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pontine Glioma - The report reviews pipeline therapeutics for Pontine Glioma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pontine Glioma therapeutics and enlists all their major and minor projects - The report assesses Pontine Glioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pontine Glioma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pontine Glioma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pontine Glioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Pontine Glioma Overview 6 Therapeutics Development 7 Pipeline Products for Pontine Glioma - Overview 7 Pontine Glioma - Therapeutics under Development by Companies 8 Pontine Glioma - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Pontine Glioma - Products under Development by Companies 11 Pontine Glioma - Companies Involved in Therapeutics Development 12 Arog Pharmaceuticals, Inc. 12 Burzynski Research Institute, Inc. 13 Loxo Oncology, Inc. 14 Medicenna Therapeutics, Inc. 15 Medivation, Inc. 16 Novogen Limited 17 Sanofi 18 Pontine Glioma - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 Antineoplaston Therapy - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 cabazitaxel - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 crenolanib besylate - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 LOXO-101 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 MDNA-55 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ORX-101 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 pidilizumab - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Trilexium - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Pontine Glioma - Recent Pipeline Updates 41 Pontine Glioma - Dormant Projects 51 Pontine Glioma - Product Development Milestones 52 Featured News & Press Releases 52 Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant 52 Jun 04, 2015: Studies Confirm TRXE-009 Crosses the Blood-brain Barrier 52 May 08, 2015: Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells 53 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56
List of Tables
Number of Products under Development for Pontine Glioma, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Pontine Glioma - Pipeline by Arog Pharmaceuticals, Inc., H1 2016 12 Pontine Glioma - Pipeline by Burzynski Research Institute, Inc., H1 2016 13 Pontine Glioma - Pipeline by Loxo Oncology, Inc., H1 2016 14 Pontine Glioma - Pipeline by Medicenna Therapeutics, Inc., H1 2016 15 Pontine Glioma - Pipeline by Medivation, Inc., H1 2016 16 Pontine Glioma - Pipeline by Novogen Limited, H1 2016 17 Pontine Glioma - Pipeline by Sanofi, H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Pontine Glioma Therapeutics - Recent Pipeline Updates, H1 2016 41 Pontine Glioma - Dormant Projects, H1 2016 51
List of Figures
Number of Products under Development for Pontine Glioma, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Targets, H1 2016 20 Number of Products by Stage and Targets, H1 2016 20 Number of Products by Mechanism of Actions, H1 2016 22 Number of Products by Stage and Mechanism of Actions, H1 2016 22 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growtRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.